Loading clinical trials...
Loading clinical trials...
APhase 2 Open Label, Study to Evaluate Safety, Pharmacokinetics & Efficacy of Oral Contrast Agent, NX9 for Delineation of Bowel Anatomy at CT Imaging With/Without IV Contrast in Subjects With Cancer or GI Disease Typically Evaluated With CT
Conditions
Interventions
NX9 Oral Contrast Agent
Locations
2
United States
Mayo Clinic
Rochester, Minnesota, United States
University of Washington
Seattle, Washington, United States
Start Date
August 1, 2020
Primary Completion Date
November 1, 2021
Completion Date
December 1, 2021
Last Updated
January 18, 2022
Lead Sponsor
Nextrast, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions